Diazepam intranasal spray

Drug Profile

Diazepam intranasal spray

Alternative Names: DZNS; Plumiaz; SK-DZNS

Latest Information Update: 17 Oct 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator SK Holdings
  • Developer Acorda Therapeutics
  • Class Antiepileptic drugs; Anxiolytics; Benzodiazepines; Benzodiazepinones; Hypnosedatives; Muscle relaxants; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epilepsy
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Epilepsy

Most Recent Events

  • 10 Jun 2016 Acorda Therapeutics completes a pharmacokinetics phase I trial in Healthy volunteers in USA (Intranasal, Spray) (NCT02663999)
  • 24 May 2016 Discontinued - Preregistration for Epilepsy in USA (Intranasal)
  • 29 Feb 2016 Acorda Therapeutics announces intention to submit NDA to the US FDA in 2017 (Acorda Therapeutics, Form 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top